DK3254681T3 - N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt - Google Patents

N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt Download PDF

Info

Publication number
DK3254681T3
DK3254681T3 DK17180587.2T DK17180587T DK3254681T3 DK 3254681 T3 DK3254681 T3 DK 3254681T3 DK 17180587 T DK17180587 T DK 17180587T DK 3254681 T3 DK3254681 T3 DK 3254681T3
Authority
DK
Denmark
Prior art keywords
pyridin
difluorphenyl
cyclohepta
imidazo
piperidin
Prior art date
Application number
DK17180587.2T
Other languages
English (en)
Inventor
Daniel Richard Roberts
Richard Raymond Schartman
Chenkou Wei
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3254681(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3254681T3 publication Critical patent/DK3254681T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17180587.2T 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt DK3254681T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
EP13708603.9A EP2820016B1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Publications (1)

Publication Number Publication Date
DK3254681T3 true DK3254681T3 (da) 2019-09-30

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13708603.9T DK2820016T3 (da) 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt
DK17180587.2T DK3254681T3 (da) 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13708603.9T DK2820016T3 (da) 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt

Country Status (25)

Country Link
US (1) US8759372B2 (da)
EP (2) EP3254681B1 (da)
JP (2) JP6208154B2 (da)
KR (2) KR102220969B1 (da)
CN (1) CN104136437B (da)
AU (1) AU2013226361B2 (da)
BR (1) BR112014021032B1 (da)
CA (1) CA2865585C (da)
CY (2) CY1119448T1 (da)
DK (2) DK2820016T3 (da)
EA (1) EA025358B1 (da)
ES (2) ES2642737T3 (da)
HK (1) HK1248111B (da)
HR (2) HRP20171620T1 (da)
HU (2) HUE047050T2 (da)
IL (1) IL234272B (da)
LT (2) LT3254681T (da)
MX (1) MX352171B (da)
NO (1) NO2935439T3 (da)
PL (2) PL2820016T3 (da)
PT (2) PT3254681T (da)
RS (2) RS56556B1 (da)
SG (1) SG11201404834XA (da)
SI (2) SI3254681T1 (da)
WO (1) WO2013130402A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347229B (es) 2012-01-26 2017-04-19 Christopher J Soares Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
BR112014021032B1 (pt) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
KR20220025914A (ko) 2015-03-06 2022-03-03 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
IL265099B1 (en) * 2016-09-02 2024-05-01 Christopher J Soares Medicinal compositions containing an effective amount of a calcitonin gene-related peptide (CGRP) receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of glaucoma
KR20190043602A (ko) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
MY201105A (en) 2017-02-01 2024-02-06 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
KR20200135465A (ko) * 2018-03-25 2020-12-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 관련 장애를 위한 리메게판트
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US20210338654A1 (en) * 2019-01-20 2021-11-04 Biohaven Pharmaceutical Holding Company Ltd. Cgrp antagonists for treating migraine breakthrough
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
AR126954A1 (es) * 2021-09-02 2023-12-06 Biohaven Pharm Holding Co Ltd Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164A (zh) * 2022-01-27 2023-08-08 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005085228A1 (ja) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. シクロアルカノピリジン誘導体
CA2583536A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
EP1804919B1 (en) 2004-10-22 2011-03-30 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CA2649158A1 (en) 2006-04-10 2007-10-25 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
BR112014021032B1 (pt) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende

Also Published As

Publication number Publication date
CY1119448T1 (el) 2018-03-07
KR20200016993A (ko) 2020-02-17
NO2935439T3 (da) 2018-03-31
HUE034936T2 (hu) 2018-03-28
CA2865585A1 (en) 2013-09-06
CN104136437A (zh) 2014-11-05
ES2642737T3 (es) 2017-11-17
LT2820016T (lt) 2017-10-25
BR112014021032A2 (da) 2017-06-20
SI3254681T1 (sl) 2019-10-30
KR20140130140A (ko) 2014-11-07
PT2820016T (pt) 2017-10-18
PL3254681T3 (pl) 2019-12-31
CY1122121T1 (el) 2020-11-25
KR102076118B1 (ko) 2020-02-11
HRP20171620T1 (hr) 2017-12-01
DK2820016T3 (da) 2017-11-13
HRP20191655T1 (hr) 2019-12-13
EA201491585A1 (ru) 2015-01-30
CN104136437B (zh) 2016-05-11
WO2013130402A1 (en) 2013-09-06
EA025358B1 (ru) 2016-12-30
AU2013226361B2 (en) 2017-09-21
KR102220969B1 (ko) 2021-02-25
MX352171B (es) 2017-11-13
HUE047050T2 (hu) 2020-04-28
ES2746031T3 (es) 2020-03-04
JP2017226693A (ja) 2017-12-28
BR112014021032B1 (pt) 2022-09-27
JP6476253B2 (ja) 2019-02-27
CA2865585C (en) 2019-12-10
PT3254681T (pt) 2019-10-01
EP3254681B1 (en) 2019-06-19
SI2820016T1 (sl) 2017-11-30
US8759372B2 (en) 2014-06-24
RS59295B1 (sr) 2019-10-31
JP2015511581A (ja) 2015-04-20
EP2820016A1 (en) 2015-01-07
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
EP3254681A1 (en) 2017-12-13
IL234272B (en) 2018-10-31
US20130225636A1 (en) 2013-08-29
AU2013226361A1 (en) 2014-10-16
RS56556B1 (sr) 2018-02-28
LT3254681T (lt) 2019-09-25
SG11201404834XA (en) 2014-09-26
JP6208154B2 (ja) 2017-10-04
HK1248111B (zh) 2020-04-17
EP2820016B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
DK3254681T3 (da) N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
KR102161364B9 (ko) LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
HK1217488A1 (zh) -二氨基- -氟苄基 -吡唑并 吡啶- -基 嘧啶- -基}甲基氨基甲酸甲酯的形式
IL227496B (en) Pyrazolo[4,3–b]pyridines are converted as drugs
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1215026A1 (zh) 作爲 抑制劑的新穎的 -二氫- -吡咯並 吡啶- -基 -喹唑啉胺和 -二氫- -吲哚- -基 -喹唑啉胺衍生物
EP2888260A4 (en) SUBSTITUTED AZAINDOLE COMPOUNDS, THEIR SALTS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
BR112013022948A2 (pt) derivados de pirido [2,3 - b] pirazina e seus usos terapêuticos
HK1208029A1 (en) Imidazopyridine derivatives
BR112013013282A2 (pt) compostos de oxazolo[5,4-b]piridin-5-ila
HK1214244A1 (zh) 咪唑並吡啶衍生物
CO7020916A2 (es) Utilizacion en terapeutica de derivados de imidazopiridina